Investors of Rocket Pharmaceuticals Urged to Act Amid Class Action Deadline Approaching

Class Action Alert: Rocket Pharmaceuticals Investors



Faruqi & Faruqi, LLP, a prominent national securities law firm, is drawing attention to a pending class action lawsuit involving Rocket Pharmaceuticals, Inc., known by its ticker symbol RCKT. The lawsuit is particularly pertinent for those who purchased or acquired shares between February 27, 2025, and May 26, 2025. The firm encourages affected investors to be proactive as they navigate this challenging landscape.

Important Deadline Approaching



Those affected need to be aware of the impending deadline of August 11, 2025, to seek the role of lead plaintiff in this class action. The lead plaintiff has significant responsibilities, including guiding the litigation process and representing the interests of the class members. Investors can contact Faruqi & Faruqi directly through their partner, Josh Wilson, who specializes in securities litigation, to discuss their legal rights and options available.

Allegations Against Rocket Pharmaceuticals



The class action alleges that Rocket Pharmaceuticals misled investors by conveying overly positive statements regarding their operations while keeping critical information concealed. This included details about the safety and clinical trial protocol for their therapy, RP-A501. Notably, the complaint highlights that serious adverse events (SAEs), including fatalities, were known risks that the company failed to disclose at the appropriate times, such as during the amendment of the trial protocol.

The contention is that Rocket executed a protocol amendment to include a new immunomodulatory agent in the treatment regimen but neglected to inform stakeholders. Consequently, this lack of transparency led to inflated stock prices, which dropped significantly following the company's announcement on May 27, 2025, of the FDA placing a clinical hold on the Phase 2 trial due to a serious incident involving a patient.

Price Drop Impact



On the announcement date, Rocket's stock plummeted roughly 37%, dropping from $6.27 per share to $2.33 per share within a single trading session—an alarming decline that underscores the gravity of investors' losses. This drastic shift highlights the potential damages stakeholders may claim as part of the class action, presenting a vital opportunity for investors to join forces in pursuit of redress.

How to Get Involved



Any member of the putative class has the right to move the Court to serve as lead plaintiff, with the possibility to choose legal representation of their preference or remain an absent class member. It's important to note that the ability to recover damages is not contingent upon the decision to act as a lead plaintiff. Faruqi & Faruqi is reaching out to persons who possess information pertaining to Rocket's actions, including whistleblowers, prior employees, and current shareholders, to aid in strengthening the case.

Conclusion



With the deadline for involvement fast approaching, affected investors are encouraged to act swiftly. By mobilizing together, shareholders can significantly impact the outcome of the litigation process against Rocket Pharmaceuticals. For further information regarding the class action lawsuit or to consult with a legal expert, potential claimants can visit Faruqi & Faruqi's website or contact the firm directly.

Faruqi & Faruqi has a storied history of securing hundreds of millions for investors since its founding in 1995, proving to be a dependable ally in the often-complex arena of securities law.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.